Capstone Investment Advisors LLC Cuts Stock Position in Haleon plc (NYSE:HLN)

Capstone Investment Advisors LLC trimmed its stake in shares of Haleon plc (NYSE:HLN) by 43.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 15,279 shares of the company’s stock after selling 11,683 shares during the period. Capstone Investment Advisors LLC’s holdings in Haleon were worth $162,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Manning & Napier Advisors LLC acquired a new stake in Haleon in the 2nd quarter worth about $2,833,000. Chartwell Investment Partners LLC boosted its stake in shares of Haleon by 107.8% in the third quarter. Chartwell Investment Partners LLC now owns 475,415 shares of the company’s stock worth $5,030,000 after acquiring an additional 246,594 shares during the last quarter. Cetera Advisors LLC increased its position in shares of Haleon by 524.3% during the first quarter. Cetera Advisors LLC now owns 81,991 shares of the company’s stock worth $696,000 after purchasing an additional 68,857 shares in the last quarter. Cetera Investment Advisers raised its stake in Haleon by 106.3% in the 1st quarter. Cetera Investment Advisers now owns 233,788 shares of the company’s stock valued at $1,985,000 after purchasing an additional 120,447 shares during the last quarter. Finally, Townsquare Capital LLC lifted its holdings in Haleon by 29.8% in the 3rd quarter. Townsquare Capital LLC now owns 475,618 shares of the company’s stock valued at $5,032,000 after purchasing an additional 109,217 shares in the last quarter. Institutional investors and hedge funds own 6.67% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on HLN. Morgan Stanley increased their target price on shares of Haleon from $9.90 to $10.95 and gave the company an “overweight” rating in a research report on Friday, September 20th. UBS Group raised shares of Haleon to a “strong-buy” rating in a research note on Tuesday, October 1st. The Goldman Sachs Group lowered Haleon from a “buy” rating to a “neutral” rating in a research report on Tuesday, August 6th. Finally, Berenberg Bank started coverage on Haleon in a research report on Tuesday, August 6th. They set a “buy” rating on the stock. One analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $10.95.

Haleon Stock Performance

NYSE:HLN opened at $9.66 on Monday. The company’s 50-day moving average is $9.92 and its two-hundred day moving average is $9.43. Haleon plc has a 1-year low of $7.89 and a 1-year high of $10.80. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.84 and a quick ratio of 0.58. The firm has a market capitalization of $43.73 billion, a price-to-earnings ratio of 28.41, a PEG ratio of 2.92 and a beta of 0.30.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.